Diabetic Ketoacidosis News and Research RSS Feed - Diabetic Ketoacidosis News and Research

Diabetic ketoacidosis – (DKA) or diabetic coma occurs when a diabetic does not properly balance their insulin intake with their diet or activity.
GlucoMen announces launch of innovative new way to better manage diabetes

GlucoMen announces launch of innovative new way to better manage diabetes

GlucoMen are delighted to announce the launch of an innovative new way for people with diabetes to manage their condition better, with the new GlucoMen Areo blood glucose meter. [More]
Promising results for low-dose insulin in paediatric diabetic ketoacidosis

Promising results for low-dose insulin in paediatric diabetic ketoacidosis

Results of a randomised trial suggest that low-dose insulin may be at least as good as standard-dose insulin for the treatment of children with diabetic ketoacidosis. [More]
Jardiance (empagliflozin) tablets now available in U.S. for people with diabetes

Jardiance (empagliflozin) tablets now available in U.S. for people with diabetes

Jardiance (empagliflozin) tablets are now available by prescription in pharmacies across the United States, including Walgreens, Rite Aid, Kroger and many other leading chain and independent retailers, according to Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company. [More]
Using a nanotech microchip to diagnose type 1 diabetes: an interview with Dr. Brian Feldman, Stanford School of Medicine

Using a nanotech microchip to diagnose type 1 diabetes: an interview with Dr. Brian Feldman, Stanford School of Medicine

The most common form of diabetes is sometimes referred to as metabolic diabetes, which is the diabetes most people are very familiar with, type 2 diabetes. This form of diabetes is most prevalent in people that are overweight or obese. Historically, it has been confined to adults or older patients but it has been on the rise as the global obesity problem has continued to worsen. [More]
Lilly and Boehringer Ingelheim's Basaglar (insulin glargine injection) gets FDA's tentative approval

Lilly and Boehringer Ingelheim's Basaglar (insulin glargine injection) gets FDA's tentative approval

The U.S. Food and Drug Administration today granted tentative approval for Basaglar (insulin glargine injection), which is indicated to improve glycemic control in adults with type 2 diabetes and in combination with mealtime insulin in adults and pediatric patients with type 1 diabetes. [More]
UChicago Medicine and Advocate Health Care wins NIH grant to find new ways to prevent type 1 diabetes

UChicago Medicine and Advocate Health Care wins NIH grant to find new ways to prevent type 1 diabetes

The University of Chicago Medicine and Advocate Children's Hospital / Advocate Health Care have received a five-year, $1.8-million grant from the National Institutes of Health to find new ways to delay and prevent type 1 diabetes. The grant will establish the first Type 1 Diabetes TrialNet Clinical Center in Chicago. [More]
Sanofi, MannKind sign licensing agreement to develop and commercialize Afrezza Inhalation Powder

Sanofi, MannKind sign licensing agreement to develop and commercialize Afrezza Inhalation Powder

Sanofi and MannKind Corporation announced today that they have entered into a worldwide exclusive licensing agreement for development and commercialization of Afrezza (insulin human) Inhalation Powder, a new rapid-acting inhaled insulin therapy for adults with type 1 and type 2 diabetes. [More]
GSK announces availability of once-weekly Tanzeum in pharmacies throughout the U.S.

GSK announces availability of once-weekly Tanzeum in pharmacies throughout the U.S.

GSK today announced that once-weekly Tanzeum (albiglutide), a prescription injectable treatment for type 2 diabetes in adults, as an adjunct to diet and exercise, is now available in pharmacies throughout the U.S. [More]
Afrezza gets FDA approval to improve glycemic control in adults with diabetes mellitus

Afrezza gets FDA approval to improve glycemic control in adults with diabetes mellitus

The U.S. Food and Drug Administration today approved Afrezza (insulin human) Inhalation Powder, a rapid-acting inhaled insulin to improve glycemic control in adults with diabetes mellitus. Afrezza is a rapid-acting inhaled insulin that is administered at the beginning of each meal, or within 20 minutes after starting a meal. [More]
Data from phase III trials supports safety, efficacy of linagliptin in treating T2D in African-American adults

Data from phase III trials supports safety, efficacy of linagliptin in treating T2D in African-American adults

Data from a retrospective pooled analysis of eight phase III trials (two 18-week and six 24-week) of linagliptin 5 mg once-daily, showed reductions from baseline A1c at 18 (eight trials) and 24 (six trials) weeks compared to placebo in African-American adults with type 2 diabetes (T2D), [More]
FDA approves GSK's Tanzeum as once-weekly treatment for type 2 diabetes

FDA approves GSK's Tanzeum as once-weekly treatment for type 2 diabetes

GlaxoSmithKline plc today announced that the US Food and Drug Administration has approved Tanzeum (albiglutide) for injection, for subcutaneous use, as a once-weekly treatment for type 2 diabetes. Tanzeum has been approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. [More]
Diabetic Ketoacidosis is disproportionately high among youth

Diabetic Ketoacidosis is disproportionately high among youth

Diabetic ketoacidosis (DKA), a life-threatening but preventable condition, remains an important problem for youth with diabetes and their families. Diabetic ketoacidosis is due to a severe lack of insulin and it is often the presenting symptom of type 1 diabetes. It can also be present at the onset of type 2 diabetes. [More]
Study: Investigational drug effective in reducing mucormycosis infections

Study: Investigational drug effective in reducing mucormycosis infections

With very few treatment options available to fight deadly mucormycosis infections, a new Los Angeles Biomedical Research Institute (LA BioMed) study holds hope for adding to the arsenal of therapies physicians have to combat an increasingly common infection afflicting people with weakened immune systems. [More]
Mylan Pharmaceuticals launches Repaglinide Tablets, 0.5 mg, 1 mg and 2 mg

Mylan Pharmaceuticals launches Repaglinide Tablets, 0.5 mg, 1 mg and 2 mg

Mylan Inc. today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Repaglinide Tablets, 0.5 mg, 1 mg and 2 mg. This product is the generic version of Novo Nordisk's Prandin, which is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. [More]
FDA approves Farxiga tablets to improve glycemic control in adults with type 2 diabetes mellitus

FDA approves Farxiga tablets to improve glycemic control in adults with type 2 diabetes mellitus

AstraZeneca and Bristol-Myers Squibb Company announced the U.S. Food and Drug Administration approved Farxiga™ [far-SEE-ga] (dapagliflozin), a once-daily oral treatment indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. [More]

EKF Diagnostics to exhibit two POC testing analyzers for diabetes management at Arab Health

EKF Diagnostics, the global in vitro diagnostics business, will be exhibiting two newly introduced point-of-care testing analyzers for rapid assessment of diabetes and related conditions. The Quo-Lab glycated haemoglobin analyzer and STAT-Site M ß-HB will both be demonstrated on the Welsh Assembly Government Stand Z1D30 in Zabeel Hall 1, Arab Health, Dubai International Convention & Exhibition Centre, 27 - 30 January 2014. [More]
Research finding could lead to development of vaccine and therapies for mucormycosis

Research finding could lead to development of vaccine and therapies for mucormycosis

Mucormycosis is a deadly infection that strikes people with weakened immune systems when certain types of fungi, called Mucorales, invade the patients' cells. A novel protein on the surface of the Mucorales cells, called CotH, makes this invasion possible. [More]
Janssen receives complete response letter for canagliflozin/metformin FDC therapy for type 2 diabetes

Janssen receives complete response letter for canagliflozin/metformin FDC therapy for type 2 diabetes

Janssen Research & Development, LLC (Janssen) today announced it has received from the U.S. Food and Drug Administration (FDA) a complete response letter regarding its New Drug Application (NDA) for a fixed-dose combination (FDC) of canagliflozin and immediate-release metformin to treat adults with type 2 diabetes. [More]
Diets and the famine reaction: an interview with Associate Professor Amanda Salis, University of Sydney

Diets and the famine reaction: an interview with Associate Professor Amanda Salis, University of Sydney

The statistic that you often hear is that 95% of diets fail, but in actual fact, emerging research is now showing that it’s around 70% of diets that fail. That means that around 30% of people who are losing weight are actually keeping it off. So we’re doing better now than we were doing in the past, but there’s still work to be done. [More]
Boehringer Ingelheim, Lilly present post-hoc analysis data from linagliptin clinical trials at EASD 2013

Boehringer Ingelheim, Lilly present post-hoc analysis data from linagliptin clinical trials at EASD 2013

Boehringer Ingelheim and Eli Lilly and Company today announced results from two post-hoc, pooled analyses of data from placebo-controlled clinical trials, which examined the safety of the dipeptidyl peptidase-4 inhibitor linagliptin in adults with type 2 diabetes. [More]